IWC
LCTX icon

Integrated Wealth Concepts’s Lineage Cell Therapeutics LCTX Stock Holding History

Integrated Wealth Concepts’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$12K – 1373
2022
Q4 		$12K Buy
+10,000
New +$12.6K ﹤0.01% 1032
2022
Q3 		– Sell
-10,000
Closed -$16K – 985
2022
Q2 		$16K Hold
10,000
– – ﹤0.01% 974
2022
Q1 		$15K Buy
+10,000
New +$15.5K ﹤0.01% 933
2021
Q2 		– Sell
-10,000
Closed -$24K – 821
2021
Q1 		$24K Buy
+10,000
New +$24K ﹤0.01% 731

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Integrated Wealth Concepts's LCTX Position: Q1 2023 in Review

Integrated Wealth Concepts sold out of Lineage Cell Therapeutics (LCTX) in Q1 2023, closing a stake of 10,000 shares — an estimated $12K sold.

Integrated Wealth Concepts first reported a position in LCTX in Q1 2021 and held it in 4 quarters. The position peaked at $24K in Q1 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

  • Integrated Wealth Concepts reported no remaining Lineage Cell Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Integrated Wealth Concepts sold 10,000 Lineage Cell Therapeutics shares in Q1 2023, an estimated $12K.
  • Integrated Wealth Concepts first reported a position in Lineage Cell Therapeutics in Q1 2021 and held it in 4 quarters.
  • Integrated Wealth Concepts's Lineage Cell Therapeutics position peaked at $24K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on Integrated Wealth Concepts's 13F filing for Q1 2023, filed 3 May 2023.